30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

Oncternal Therapeutics Inc (ONCT)

Track

The most recent insider transaction occurred on October 14, 2024, with an Officer proposing a sale of 4,681 shares. Prior to this, there were several buy transactions in April 2024, notably by Robert James Wills and David F. Hale. Earlier in 2023, significant buy transactions were made by executives including the Chief Executive Officer, Chief Scientific Officer, and Chief Medical Officer.
Stock chart
Ticker: ONCT Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Yazji Salim
Officer
1 sale — total 5,009 USD
Proposed sale 14 Oct 2024
Value US$3,385,006.40 | Price 278.52 | Shares 52,283
Buy 8 Apr 2024
Value US$1,161,216.29 | Price 463.56 | Shares 88,799
Buy 28 Mar 2024
Value US$58,602.37 | Price 8.48 | Shares 6,914
Sale 23 Feb 2024
Value US$8,859.20 | Price 9.04 | Shares 980
Buy 23 Feb 2024
Value US$2,404.64 | Price 9.04 | Shares 266
Buy 23 Feb 2024
Value US$6,454.56 | Price 9.04 | Shares 714
Buy 14 Jun 2023
Value US$1,079.10 | Price 0.36 | Shares 3,000
Buy 12 Jun 2023
Value US$8,745.00 | Price 0.35 | Shares 25,000
Buy 14 Apr 2023
Value US$652.50 | Price 0.29 | Shares 2,250
Buy 14 Apr 2023
Value US$14,277.25 | Price 0.30 | Shares 47,750
Buy 14 Apr 2023
Value US$1,500.00 | Price 0.30 | Shares 5,000
Buy 13 Apr 2023
Value US$29,000.00 | Price 0.29 | Shares 100,000
Buy 13 Apr 2023
Value US$8,961.00 | Price 0.30 | Shares 30,000
Buy 13 Apr 2023
Value US$2,850.00 | Price 0.29 | Shares 10,000
Buy 13 Apr 2023
Value US$2,900.00 | Price 0.29 | Shares 10,000
Buy 12 Apr 2023
Value US$2,850.00 | Price 0.29 | Shares 10,000
Buy 12 Apr 2023
Value US$4,350.00 | Price 0.29 | Shares 15,000
Buy 28 Mar 2022
Value US$3,500.00 | Price 1.40 | Shares 2,500
Buy 25 Mar 2022
Value US$3,182.43 | Price 1.49 | Shares 2,136
Buy 25 Mar 2022
Value US$7.40 | Price 1.48 | Shares 5
Buy 25 Mar 2022
Value US$516.20 | Price 1.45 | Shares 356
Buy 24 Mar 2022
Value US$4.35 | Price 1.45 | Shares 3
Buy 28 Jan 2022
Value US$4,125.00 | Price 1.65 | Shares 2,500
Buy 28 Jan 2022
Value US$8,150.00 | Price 1.63 | Shares 5,000
Buy 27 Jan 2022
Value US$8,500.00 | Price 1.70 | Shares 5,000
Buy 27 Jan 2022
Value US$9,000.00 | Price 1.80 | Shares 5,000
Buy 27 Jan 2022
Value US$42,080.00 | Price 1.68 | Shares 25,000
Buy 27 Jan 2022
Value US$15,130.00 | Price 1.78 | Shares 8,500
Buy 27 Jan 2022
Value US$16,900.00 | Price 1.69 | Shares 10,000
Buy 11 Jun 2021
Value US$8,175.00 | Price 5.45 | Shares 1,500
Buy 1 Sep 2020
Value US$150,000.90 | Price 2.10 | Shares 71,429
Buy 21 Jul 2020
Value US$2,499,997.75 | Price 2.38 | Shares 1,049,317
Buy 21 Jul 2020
Value US$23,825.00 | Price 2.38 | Shares 10,000
Buy 21 Jul 2020
Value US$99,998.29 | Price 2.38 | Shares 41,972
Buy 21 May 2020
Value US$0.00 | Price 0.00 | Shares 17,412
Buy 26 Jun 2018
Value US$83,750.00 | Price 16.75 | Shares 5,000
Sale 20 Jun 2018
Value US$139,707.96 | Price 19.01 | Shares 7,351
Sale 20 Jun 2018
Value US$176,350.18 | Price 19.01 | Shares 9,279
Sale 5 Jan 2018
Value US$26,478.27 | Price 11.13 | Shares 2,379
Sale 5 Jan 2018
Value US$8,546.22 | Price 12.02 | Shares 711
Sale 5 Jan 2018
Value US$42,549.99 | Price 11.13 | Shares 3,823
Sale 5 Jan 2018
Value US$13,726.84 | Price 12.02 | Shares 1,142
Sale 5 Jan 2018
Value US$62,639.64 | Price 11.13 | Shares 5,628
Sale 5 Jan 2018
Value US$20,205.62 | Price 12.02 | Shares 1,681
Buy 29 Sep 2017
Value US$0.00 | Price 0.00 | Shares 565,291
Sale 28 Oct 2016
Value US$3,850.00 | Price 7.70 | Shares 500
Buy 14 Oct 2016
Value US$6,249,999.69 | Price 0.81 | Shares 7,716,049
Buy 16 Jun 2016
Value US$65,360.00 | Price 0.65 | Shares 100,000
Buy 1 Mar 2016
Value US$26,400.00 | Price 0.60 | Shares 44,000
Buy 26 Jan 2016
Value US$2,600.00 | Price 0.65 | Shares 4,000
Buy 25 Jan 2016
Value US$8,067.06 | Price 0.63 | Shares 12,813
Buy 19 Jan 2016
Value US$12,427.50 | Price 0.50 | Shares 25,000
Buy 15 Jan 2016
Value US$10,888.67 | Price 0.49 | Shares 22,100
Buy 14 Jan 2016
Value US$1,376.92 | Price 0.47 | Shares 2,900
Buy 24 Dec 2015
Value US$79.00 | Price 0.79 | Shares 100
Buy 23 Dec 2015
Value US$474.00 | Price 0.79 | Shares 600
Buy 22 Dec 2015
Value US$1,019.46 | Price 0.78 | Shares 1,307
Buy 21 Dec 2015
Value US$31,122.00 | Price 0.78 | Shares 39,900
Buy 19 May 2015
Value US$30,625.00 | Price 1.25 | Shares 24,500
Buy 14 May 2015
Value US$35,711.20 | Price 0.98 | Shares 36,440
Buy 13 May 2015
Value US$8,536.00 | Price 0.88 | Shares 9,700
Buy 11 May 2015
Value US$3,088.00 | Price 0.80 | Shares 3,860
Buy 8 May 2015
Value US$20,381.60 | Price 0.80 | Shares 25,477
Buy 8 May 2015
Value US$40,000.00 | Price 0.80 | Shares 50,000
Buy 22 Apr 2015
Value US$7,200.00 | Price 0.72 | Shares 10,000
Buy 21 Apr 2015
Value US$5,435.76 | Price 0.71 | Shares 7,656
Buy 20 Apr 2015
Value US$2,845.44 | Price 0.72 | Shares 3,952
Buy 15 Apr 2015
Value US$2,376.00 | Price 0.72 | Shares 3,300
Buy 10 Apr 2015
Value US$10,988.00 | Price 0.67 | Shares 16,400
Buy 23 Sep 2014
Value US$3,750.00 | Price 0.75 | Shares 5,000
Buy 17 Sep 2014
Value US$7,432.00 | Price 0.74 | Shares 10,000
Buy 21 Aug 2014
Value US$10,000.00 | Price 1.00 | Shares 10,000
Buy 20 Aug 2014
Value US$10,000.00 | Price 1.00 | Shares 10,000
Buy 19 Aug 2014
Value US$8,448.18 | Price 1.01 | Shares 8,348
Buy 15 Aug 2014
Value US$1,652.00 | Price 1.00 | Shares 1,652
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2024-10-15 2024-10-14 PrS Proposed sale
2.5
Yazji Salim

Officer

Officer
52,283
278.52
US$3,385,006 		52,283 278.52 US$3,385,006
2024-04-10 2024-04-08 B Purchase
1.8
Wills Robert James
Non-Executive Director
88,799 -38.0%
463.56
US$1,161,216 		88,799 -38.0% 463.56 US$1,161,216
2024-04-01 2024-03-28 B Purchase
1.8
Wills Robert James
Non-Executive Director
84,740 +30.8%
12.58
US$1,515,212 		84,740 +30.8% 12.58 US$1,515,212
2024-02-27 2024-02-23 S Sale
1.8
Wills Robert James
Non-Executive Director
980 -100.0%
9.04
US$8,859 		980 -100.0% 9.04 US$8,859
2024-02-27 2024-02-23 B Purchase
1.4
HALE DAVID F
Non-Executive Director
266 +0.9%
9.04
US$2,405 		266 +0.9% 9.04 US$2,405
2024-02-27 2024-02-23 B Purchase
1.4
HALE DAVID F
Non-Executive Director
714 +inf%
9.04
US$6,455 		714 +inf% 9.04 US$6,455
2023-06-14 2023-06-14 B Purchase
1.9
Kaufmann Gunnar F.

Chief Scientific Officer

Officer
3,000 +3.3%
0.36
US$1,079 		3,000 +3.3% 0.36 US$1,079
2023-06-14 2023-06-12 B Purchase
1.9
Kaufmann Gunnar F.

Chief Scientific Officer

Officer
25,000 +37.5%
0.35
US$8,745 		25,000 +37.5% 0.35 US$8,745
2023-04-17 2023-04-14 B Purchase
3.0
BREITMEYER JAMES B

Chief Executive Officer

Executive Director
2,250 +1.2%
0.29
US$652 		2,250 +1.2% 0.29 US$652
2023-04-17 2023-04-14 B Purchase
3.0
BREITMEYER JAMES B

Chief Executive Officer

Executive Director
47,750 +32.6%
0.30
US$14,277 		47,750 +32.6% 0.30 US$14,277
2023-04-14 2023-04-14 B Purchase
2.5
Yazji Salim

Chief Medical Officer

Officer
5,000 +3.1%
0.30
US$1,500 		5,000 +3.1% 0.30 US$1,500
2023-04-17 2023-04-13 B Purchase
3.0
BREITMEYER JAMES B

Chief Executive Officer

Executive Director
100,000 +214.9%
0.29
US$29,000 		100,000 +214.9% 0.29 US$29,000
2023-04-14 2023-04-13 B Purchase
2.2
VINCENT RICHARD G

Chief Financial Officer

Officer
30,000 +23.6%
0.30
US$8,961 		30,000 +23.6% 0.30 US$8,961
2023-04-14 2023-04-13 B Purchase
2.5
Yazji Salim

Chief Medical Officer

Officer
10,000 +6.7%
0.29
US$2,850 		10,000 +6.7% 0.29 US$2,850
2023-04-14 2023-04-13 B Purchase
2.3
Leavitt Chase C.

General Counsel/Secretary

Officer
10,000 +10.3%
0.29
US$2,900 		10,000 +10.3% 0.29 US$2,900
2023-04-14 2023-04-12 B Purchase
2.5
Yazji Salim

Chief Medical Officer

Officer
10,000 +7.2%
0.29
US$2,850 		10,000 +7.2% 0.29 US$2,850
2023-04-14 2023-04-12 B Purchase
2.3
Leavitt Chase C.

General Counsel/Secretary

Officer
15,000 +18.3%
0.29
US$4,350 		15,000 +18.3% 0.29 US$4,350
2022-03-28 2022-03-28 B Purchase
2.2
VINCENT RICHARD G

Chief Financial Officer

Officer
2,500 +2.9%
1.40
US$3,500 		2,500 +2.9% 1.40 US$3,500
2022-03-28 2022-03-25 B Purchase
2.2
VINCENT RICHARD G

Chief Financial Officer

Officer
2,136 +2.6%
1.49
US$3,182 		2,136 +2.6% 1.49 US$3,182
2022-03-28 2022-03-25 B Purchase
2.2
VINCENT RICHARD G

Chief Financial Officer

Officer
5 +0.0%
1.48
US$7 		5 +0.0% 1.48 US$7
2022-03-28 2022-03-25 B Purchase
2.2
VINCENT RICHARD G

Chief Financial Officer

Officer
356 +0.4%
1.45
US$516 		356 +0.4% 1.45 US$516
2022-03-28 2022-03-24 B Purchase
2.2
VINCENT RICHARD G

Chief Financial Officer

Officer
3 +0.0%
1.45
US$4 		3 +0.0% 1.45 US$4
2022-01-31 2022-01-28 B Purchase
2.2
VINCENT RICHARD G

Chief Financial Officer

Officer
2,500 +3.1%
1.65
US$4,125 		2,500 +3.1% 1.65 US$4,125
2022-01-31 2022-01-28 B Purchase
2.3
Leavitt Chase C.

General Counsel/Secretary

Officer
5,000 +12.5%
1.63
US$8,150 		5,000 +12.5% 1.63 US$8,150
2022-01-31 2022-01-27 B Purchase
2.2
VINCENT RICHARD G

Chief Financial Officer

Officer
5,000 +6.6%
1.70
US$8,500 		5,000 +6.6% 1.70 US$8,500
2022-01-31 2022-01-27 B Purchase
2.2
VINCENT RICHARD G

Chief Financial Officer

Officer
5,000 +7.1%
1.80
US$9,000 		5,000 +7.1% 1.80 US$9,000
2022-01-31 2022-01-27 B Purchase
3.0
BREITMEYER JAMES B

Chief Executive Officer

Executive Director
25,000 +116.0%
1.68
US$42,080 		25,000 +116.0% 1.68 US$42,080
2022-01-31 2022-01-27 B Purchase
2.3
Leavitt Chase C.

General Counsel/Secretary

Officer
8,500 +27.1%
1.78
US$15,130 		8,500 +27.1% 1.78 US$15,130
2022-01-31 2022-01-27 B Purchase
2.5
Yazji Salim

Chief Medical Officer

Officer
10,000 +17.5%
1.69
US$16,900 		10,000 +17.5% 1.69 US$16,900
2021-06-15 2021-06-11 B Purchase
2.3
Leavitt Chase C.

General Counsel/Secretary

Officer
1,500 +inf%
5.45
US$8,175 		1,500 +inf% 5.45 US$8,175
2020-09-02 2020-09-01 B Purchase
2.4
CARTER MICHAEL G
Non-Executive Director
71,429 +13789.4%
2.10
US$150,001 		71,429 +13789.4% 2.10 US$150,001
2020-07-23 2020-07-21 B Purchase
2.3
Shanghai Pharmaceutical (USA) Inc.
Large shareholder
1,049,317 +42.1%
2.38
US$2,499,998 		1,049,317 +42.1% 2.38 US$2,499,998
2020-07-23 2020-07-21 B Purchase
2.3
KISNER DANIEL L
Non-Executive Director
10,000 +inf%
2.38
US$23,825 		10,000 +inf% 2.38 US$23,825
2020-07-23 2020-07-21 B Purchase
2.3
AKER HAZEL M

Legal Counsel

Officer
41,972 +836.9%
2.38
US$99,998 		41,972 +836.9% 2.38 US$99,998
2020-05-22 2020-05-21 B Purchase
1.4
HALE DAVID F
Non-Executive Director
17,412
0.00
US$0 		17,412 0.00 US$0
2018-06-26 2018-06-26 B Purchase Wills Robert James

Executive Chairman

Executive Director
5,000 +3.8%
16.75
US$83,750 		5,000 +3.8% 16.75 US$83,750
2018-06-22 2018-06-20 S Sale DOGGRELL HENRY PATTON

VP, Chief Legal Officer
7,351 -14.4%
19.01
US$139,708 		7,351 -14.4% 19.01 US$139,708
2018-06-22 2018-06-20 S Sale Shackelford Jason T

Prin Fin. & Acct. Officer
9,279 -32.3%
19.01
US$176,350 		9,279 -32.3% 19.01 US$176,350
2018-01-09 2018-01-05 S Sale Shackelford Jason T

Prin Fin. & Acct. Officer

Officer
2,379 -7.6%
11.13
US$26,478 		2,379 -7.6% 11.13 US$26,478
2018-01-09 2018-01-05 S Sale
0.5
Shackelford Jason T

Prin Fin. & Acct. Officer

Officer
711 -2.2%
12.02
US$8,546 		711 -2.2% 12.02 US$8,546
2018-01-09 2018-01-05 S Sale DOGGRELL HENRY PATTON

VP, Chief Legal Officer

Officer
3,823 -7.0%
11.13
US$42,550 		3,823 -7.0% 11.13 US$42,550
2018-01-09 2018-01-05 S Sale DOGGRELL HENRY PATTON

VP, Chief Legal Officer

Officer
1,142 -2.0%
12.02
US$13,727 		1,142 -2.0% 12.02 US$13,727
2018-01-09 2018-01-05 S Sale HANOVER MARC STEVEN

Chief Executive Officer

Executive Director
5,628 -4.3%
11.13
US$62,640 		5,628 -4.3% 11.13 US$62,640
2018-01-09 2018-01-05 S Sale HANOVER MARC STEVEN

Chief Executive Officer

Executive Director
1,681 -1.3%
12.02
US$20,206 		1,681 -1.3% 12.02 US$20,206
2017-10-02 2017-09-29 B Purchase Pyramid Peak Foundation Large shareholder
565,291
0.00
US$0 		565,291 0.00 US$0
2017-02-28 2016-10-28 S Sale Young Diane C.

VP, Chief Medical Officer
500 -100.0%
7.70
US$3,850 		500 -100.0% 7.70 US$3,850
2016-10-17 2016-10-14 B Purchase Pyramid Peak Foundation Large shareholder
7,716,049 +25.3%
0.81
US$6,250,000 		7,716,049 +25.3% 0.81 US$6,250,000
2016-06-20 2016-06-16 B Purchase Wills Robert James

Executive Chairman

Executive Director
100,000 +9.1%
0.65
US$65,360 		100,000 +9.1% 0.65 US$65,360
2016-03-02 2016-03-01 B Purchase GLASS J KENNETH Non-Executive Director
44,000 +31.5%
0.60
US$26,400 		44,000 +31.5% 0.60 US$26,400
2016-01-26 2016-01-26 B Purchase HANOVER MARC STEVEN

Chief Executive Officer

Executive Director
4,000 +0.3%
0.65
US$2,600 		4,000 +0.3% 0.65 US$2,600
2016-01-25 2016-01-25 B Purchase HANOVER MARC STEVEN

Chief Executive Officer

Executive Director
12,813 +1.0%
0.63
US$8,067 		12,813 +1.0% 0.63 US$8,067
2016-01-19 2016-01-19 B Purchase HANOVER MARC STEVEN

Chief Executive Officer

Executive Director
25,000 +2.1%
0.50
US$12,428 		25,000 +2.1% 0.50 US$12,428
2016-01-15 2016-01-15 B Purchase HANOVER MARC STEVEN

Chief Executive Officer

Executive Director
22,100 +1.9%
0.49
US$10,889 		22,100 +1.9% 0.49 US$10,889
2016-01-15 2016-01-14 B Purchase HANOVER MARC STEVEN

Chief Executive Officer

Executive Director
2,900 +0.2%
0.47
US$1,377 		2,900 +0.2% 0.47 US$1,377
2015-12-28 2015-12-24 B Purchase GLASS J KENNETH Non-Executive Director
100 +0.1%
0.79
US$79 		100 +0.1% 0.79 US$79
2015-12-23 2015-12-23 B Purchase GLASS J KENNETH Non-Executive Director
600 +0.4%
0.79
US$474 		600 +0.4% 0.79 US$474
2015-12-23 2015-12-22 B Purchase GLASS J KENNETH Non-Executive Director
1,307 +0.9%
0.78
US$1,019 		1,307 +0.9% 0.78 US$1,019
2015-12-21 2015-12-21 B Purchase GLASS J KENNETH Non-Executive Director
39,900 +40.8%
0.78
US$31,122 		39,900 +40.8% 0.78 US$31,122
2015-05-20 2015-05-19 B Purchase GLASS J KENNETH Non-Executive Director
24,500 +inf%
1.25
US$30,625 		24,500 +inf% 1.25 US$30,625
2015-05-14 2015-05-14 B Purchase Wills Robert James

Executive Chairman

Executive Director
36,440 +57.3%
0.98
US$35,711 		36,440 +57.3% 0.98 US$35,711
2015-05-14 2015-05-13 B Purchase Wills Robert James

Executive Chairman

Executive Director
9,700 +18.0%
0.88
US$8,536 		9,700 +18.0% 0.88 US$8,536
2015-05-13 2015-05-11 B Purchase Wills Robert James

Executive Chairman

Executive Director
3,860 +7.7%
0.80
US$3,088 		3,860 +7.7% 0.80 US$3,088
2015-05-11 2015-05-08 B Purchase DOGGRELL HENRY PATTON

VP, Chief Legal Officer

Officer
25,477 +inf%
0.80
US$20,382 		25,477 +inf% 0.80 US$20,382
2015-05-11 2015-05-08 B Purchase Wills Robert James

Executive Chairman

Executive Director
50,000 +inf%
0.80
US$40,000 		50,000 +inf% 0.80 US$40,000
2015-04-23 2015-04-22 B Purchase GLASS J KENNETH Non-Executive Director
10,000 +11.4%
0.72
US$7,200 		10,000 +11.4% 0.72 US$7,200
2015-04-22 2015-04-21 B Purchase GLASS J KENNETH Non-Executive Director
7,656 +9.5%
0.71
US$5,436 		7,656 +9.5% 0.71 US$5,436
2015-04-22 2015-04-20 B Purchase GLASS J KENNETH Non-Executive Director
3,952 +5.2%
0.72
US$2,845 		3,952 +5.2% 0.72 US$2,845
2015-04-15 2015-04-15 B Purchase GLASS J KENNETH Non-Executive Director
3,300 +4.5%
0.72
US$2,376 		3,300 +4.5% 0.72 US$2,376
2015-04-13 2015-04-10 B Purchase GLASS J KENNETH Non-Executive Director
16,400 +29.0%
0.67
US$10,988 		16,400 +29.0% 0.67 US$10,988
2014-09-23 2014-09-23 B Purchase HANOVER MARC STEVEN

Interim CEO, President and COO

Executive Director
5,000 +2.4%
0.75
US$3,750 		5,000 +2.4% 0.75 US$3,750
2014-09-17 2014-09-17 B Purchase HANOVER MARC STEVEN

Interim CEO, President and COO

Executive Director
10,000 +5.0%
0.74
US$7,432 		10,000 +5.0% 0.74 US$7,432
2014-08-21 2014-08-21 B Purchase HANOVER MARC STEVEN

Interim CEO, President and COO

Executive Director
10,000 +5.3%
1.00
US$10,000 		10,000 +5.3% 1.00 US$10,000
2014-08-21 2014-08-20 B Purchase HANOVER MARC STEVEN

Interim CEO, President and COO

Executive Director
10,000 +5.6%
1.00
US$10,000 		10,000 +5.6% 1.00 US$10,000
2014-08-19 2014-08-19 B Purchase HANOVER MARC STEVEN

Interim CEO, President and COO

Executive Director
8,348 +4.9%
1.01
US$8,448 		8,348 +4.9% 1.01 US$8,448
2014-08-19 2014-08-15 B Purchase HANOVER MARC STEVEN

Interim CEO, President and COO

Executive Director
1,652 +1.0%
1.00
US$1,652 		1,652 +1.0% 1.00 US$1,652
Explore more

More insider trading research around Oncternal Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America